Olanzapine Anorexia Cachexia

PHASE3CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

December 25, 2021

Primary Completion Date

November 21, 2022

Study Completion Date

December 14, 2022

Conditions
Anorexia
Interventions
DRUG

Olanzapine 5 MG

, Olanzapine (OLZ) is an atypical antipsychotic agent that blocks multiple neurotransmitters: dopamine at D1, D2, D3 and D4 brain receptors, serotonin at 5-HT2a , 5-HT2c, 5-HT3, and 5-HT6receptors, catecholamines at alpha 1 adrenergic receptors, acetylcholine at muscarinic receptors, and histamine at H1 receptors is suggested to have a valuable role in CAC

DRUG

Placebo

Tablets containing 300 mg of microcrystalline cellulose. It will be identical to the active drug

Trial Locations (1)

11562

Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Cairo

All Listed Sponsors
lead

Cairo University

OTHER

NCT05243251 - Olanzapine Anorexia Cachexia | Biotech Hunter | Biotech Hunter